In this nationwide retrospective cohort study of 2770 major bleeding events among Asian AF patients treated with DOACs, we found that the hazard ratio for 7-day mortality in those treated with factor Xa inhibitors was twice those treated with dabigatran. This evidence concerns the gene F10 and atrial fibrillation.